NEW YORK ( TheStreet) -- Luminex Corporation (Nasdaq: LMNX) hit a new 52-week high Monday as it is currently trading at $25.22, above its previous 52-week high of $25.16 with 224,713 shares traded as of 2:05 p.m. ET. Average volume has been 318,600 shares over the past 30 days.

Luminex has a market cap of $981 million and is part of the health care sector and health services industry. Shares are up 10.8% year to date as of the close of trading on Friday.

Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries. The company has a P/E ratio of 75.9, above the average health services industry P/E ratio of 73.5 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Luminex as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Luminex Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.